3028 results about "Viral infection" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Provided are methods and compounds for treating (or for use in manufacturing a pharmaceutical dosage form to treat) viral infections by administering avermectin-based bioavailable highly permeable compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of SARS-CoV-2, dengue, chikungunya, yellow fever, Zika and other viral infections.

The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.

The invention relates to the technical field of biological detection, in particular to an MxA, CRP and SAA combined detection card and a preparation method and application thereof, and the preparation method comprises the following steps: 1) preparing silicon-coated high-performance time-resolved fluorescent microspheres; (2) marking of an MxA antibody; (3) marking a CRP antibody; (4) marking an SAA antibody; (5) preparing a conjugate pad; (6) preparing a nitrocellulose membrane; and (7) assembling the reagent strip. The silicon-coated high-performance time-resolved fluorescent microspheres with the particle size range of 190-352 nm are prepared, the dye embedding rate is high, the sensitivity is high, the monodispersity is good, the stability is good, the hydrophilicity is high, agglomeration is not prone to occurring, and the dye embedding rate is increased. The MxA, CRP and SAA combined detection card prepared from the silicon-coated high-performance time-resolved fluorescent microspheres can improve the accuracy of identifying bacterial infection and virus infection, and is beneficial to early diagnosis and treatment of acute respiratory infectious diseases.

The invention discloses a novel application of an RNF6 gene, namely, an application of screening a medicine for preventing and / or treating Zika virus infection, aiming at inhibiting expression of the RNF6 gene or knocking out the RNF6 gene. A series of functional experiments prove that the RNF6 gene promotes the replication of the Zika virus, and the purpose of reducing the replication of the Zika virus can be achieved by using an expression inhibitor of the RNF6 gene or knocking out the RNF6 gene; experimental results show that the RNF6 gene can be used as a potential target for preventing and / or treating Zika virus infection, and a new direction is provided for development of drugs for preventing and / or treating Zika virus infection targeting the RNF6 gene in the future.

A method of treating or inhibiting a viral infection in a human subject, such as a SARS-CoV-2 infection, involves inhibiting in vivo the expression or activity of one or a combination of the subject's genes required for viral infection. Single genes or subsets of genes for inhibition of activity or expression are selected from certain identified genes. Methods of administration of certain known small molecules or other therapeutics which mimic loss of function of the identified genes are provided. Similar methods for conducting screens of host genes required for viral infection are shown.

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention discloses application of a small molecule compound in prevention and treatment of plant RNA virus infection, and belongs to the technical field of biology. According to the invention, 2 '-amino-2'-deoxyguanosine (ADG) is used as a unique antiviral active component to be applied to prevention and treatment of plant RNA viruses for the first time, and broad-spectrum inhibition of various plant RNA viruses such as turnip mosaic virus (TuMV), tomato mosaic virus (ToMV) and tobacco mosaic virus (TMV) can be realized only by a low concentration of 250 [mu] M and a simple exogenous spraying mode; and after spraying, the normal growth of plants is not influenced, the risk of phytotoxicity is thoroughly avoided, the safety, high efficiency and broad spectrum of plant RNA virus prevention and control are remarkably improved, and important practical application significance is achieved for guaranteeing the yield and quality of crops in agricultural production and promoting agricultural green transformation.

The invention belongs to the technical field of medical treatment, and discloses a blood product virus inactivation system based on a synergistic effect of nano-catalysis photochemical inactivation and low-temperature plasma, the system comprises: a nano-photocatalysis inactivation module adopting titanium dioxide TiO2 and graphite phase carbon nitride g-C3N4 nano-materials as photocatalysts; the low-temperature plasma inactivation module adopts a low-temperature plasma generator to generate plasma cloud above the blood product and release active particles; the dynamic fluid stirring module is used for enabling the blood product to uniformly receive photocatalysis and plasma inactivation effects through a microfluid mixing technology so as to ensure the uniformity of virus inactivation; the sensing monitoring and intelligent feedback module is used for monitoring the residual quantity of viral nucleic acid and the activity of protein in the blood in real time by adopting a spectrum sensor and a biochemical sensor. The method can be widely applied to the fields of clinical blood transfusion, blood product manufacturing, blood disease treatment and the like, promotes the progress of a blood safety guarantee technology, reduces the virus infection risk and improves the patient safety.

The invention discloses application of jute nanocellulose or derivatives thereof in preparation of drugs or feeds for preventing and treating bee virus infection, and belongs to the technical field of bee breeding. It is found that the jute nanocellulose can significantly improve the survival rate of Italian bees infected with chronic paralysis virus (CBPV) and reduce the death rate of the Italian bees. The jute nano-cellulose can inhibit proliferation of CBPV in bees and reduce the copy number of viruses. Meanwhile, the level of intestinal probiotics reduced due to CBPV infection can be recovered, and the congenital immune defense capability of bees is improved. The jute nanocellulose can be used for preparing drugs or feed additives for preventing and treating CBPV infection, has important significance on preventing and treating chronic paralysis viruses of Italian bees, and has good market application value.

The invention provides monoclonal antibodies of H protein and N protein of canine distemper virus and application thereof in preparation of a fluorescent microsphere antigen detection test strip. The monoclonal antibody disclosed by the invention is characterized in that (1) the monoclonal antibody contains a heavy chain variable region CDV-N-3A11-VH and a light chain variable region CDV-N-3A11-VL; the amino acid sequence of the CDV-N-3A11-VH is as shown in the 1st to 116th sites of SEQ ID No.1 in a sequence table; the amino acid sequence of the CDV-N-3A11-VL is as shown in the 1st site to the 113th site of SEQ ID No.2 in a sequence table. (2) a heavy chain variable region CDV-H-1G5-VH and a light chain variable region CDV-H-1G5-VL are contained; the amino acid sequence of the CDV-H-1G5-VH is as shown in the first site to the 114 site of SEQ ID No.3 in a sequence table; the amino acid sequence of the CDV-H-1G5-VL is as shown in the 1st site to the 1st site and the 1st site to the 1st site of SEQ ID No.4 in a sequence table. The canine distemper virus fluorescent microsphere antigen test strip composed of the two antibodies is suitable for detecting canine distemper viruses in samples such as eye and nose swabs and virus cultures, is high in sensitivity and good in specificity, and can be used for early diagnosis of canine distemper virus infection.

The invention discloses an application of lactic acid (Lactate) in prevention and treatment of infection of CyHV-2 (Cyprinid Herpesvirus, CyHV-2), SVCV (Spring Viraemia of Carp Virus) and GCRV (Grass Carp Reovirus), a result of a cell line infection model shows that the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV, and the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV. Furthermore, a molecular biology experiment result shows that the transcription level of the virus related genes treated by lactic acid is obviously inhibited. Therefore, the lactic acid can be used as a medicine or an additive for preventing and treating CyHV-2, SVCV and GCRV infection, and has the advantages of low dosage and good protection effect.

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to a method for inhibiting in-vitro infection of a porcine epidemic diarrhea virus by using JPH203 and application. The JPH203 can be used for preparing an antiviral drug for inhibiting infection of the porcine epidemic diarrhea virus. JPH203 with the concentration of 5 [mu] M is added in the process that Vero cells are infected with PEDV, compared with a control group without JPH203, the virus infection condition, the protein expression quantity, the RNA content and the virus titer of the PEDV in a treatment group with JPH203 are all remarkably reduced, and it is indicated that JPH203 can be used for inhibiting in-vitro infection of the porcine epidemic diarrhea virus.

The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention discloses an application of a porcine GDPD2 gene in preparation of a medicine for inhibiting porcine epidemic diarrhea virus replication. It is found for the first time that overexpression of the porcine GDPD2 gene can effectively inhibit replication of the porcine epidemic diarrhea virus, and the porcine GDPD2 gene can serve as a target spot for inhibiting porcine epidemic diarrhea virus infection to be used for preparing related drugs.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The invention discloses an application of kaempferol in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. The kaempferol can obviously inhibit the replication of the PEDV in Vero and LLC-PK1 cells through 3C-like protease targeting the PEDV, so that the kaempferol can be used for preparing the medicine for preventing and treating the PEDV. Besides, kaempferol, as a natural substance separated from mulberries, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, and does not cause generation of drug-resistant strains and other toxic and side effects after being used for a long time; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

This invention is related to the field of biosensors. In particular, devices and methods are described which enable the quantification of biomolecules by virtue of particle speed driven by induced-charge electrophoresis. For example, a range of biomolecules can be simultaneously detected in a highly sensitive manner from a library (e.g., combination) of active particles having different shapes or fluorescent signatures. Such biomolecules are related to conditions including, but not limited to, cancer biomarkers, viral infection biomarkers, toxins, pesticides, and small molecule drugs.

The present disclosure relates generally to solid forms of the compound of Formula I:Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The invention belongs to the technical field of disease prevention and treatment and aquaculture, and relates to application of acacetin in preparation of a medicine for preventing and treating white spot syndrome. The invention discloses that the acacetin has the biological activity of resisting the white spot syndrome virus for the first time, verifies that the acacetin can obviously inhibit the replication of the white spot syndrome virus in the procambarus clarkia body, and simultaneously improves the survival rate of the procambarus clarkia infected by the white spot syndrome virus. The acacetin has a good antiviral effect on the white spot syndrome virus in crustacean aquaculture, and can be applied to prevention and treatment of aquatic animal diseases caused by the white spot syndrome virus.

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

Provided herein are stable formulations containing active ingredients, such as antiviral compositions, or antiretroviral compositions in a powder form for reconstitution for intrarectal delivery to provide pre-exposure prophylaxis (PrEP) against viral infections. The antiviral composition may be tenofovir, for HIV PrEP.

The invention discloses a monoclonal antibody which only specifically recognizes neutrophil apolipoprotein homodimer HNL / HNL and does not recognize monomer form HNL. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody realizes accurate, simple and rapid quantification of homodimer form HNL / HNL, promotes wide clinical application of the detection index, accurately distinguishes bacterial infection and virus infection, and reduces unreasonable use of antibiotics.

The invention relates to antiviral application of a membrane fusion inhibition polypeptide. The membrane fusion inhibition polypeptide is used for treating diseases caused by virus infection of pneumoviridae.